Clinical study about the safety of Suvorexant for severe sleep apnea syndrome

Clinical study about the safety of Orexin receptor antagonist Suvorexant for severe sleep apnea syndrome - Clinical study about the safety of Suvorexant for severe sleep apnea syndrome

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041180086

Enrollment

Registered

2019-03-12

Start date

2016-12-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Apnea Syndrome

Interventions

using orexin receptor antagonist Suvorexant

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient who received enough explanation about this study, and provides agreement in the document.

Exclusion criteria

Exclusion criteria: The patient 19 years or younger at the time of the agreement acquisition

Design outcomes

Primary

Measure	Time frame
Apnea hypopnea index on PSG	—

Secondary

Measure	Time frame
Epworth sleepiness scale	—

Contacts

Public ContactYuuki Mieno

Fujita Health University Hospital

mienon@fujita-hu.ac.jp+81-562-93-9241

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026